Kamada Reaffirms 2024 Targets, Unveils 2025 Guidances, Revenue Of $178M-$182M Vs. $171.18M Est. And Adj.EBITDA Of $38M-$42M
Kamada Reaffirms 2024 Targets, Unveils 2025 Guidances, Revenue Of $178M-$182M Vs. $171.18M Est. And Adj.EBITDA Of $38M-$42M
Kamada重申2024年目标,公布2025年指导,营业收入为$17800万,$18200万对比$17118万的预估,调整后EBITDA为$3800万,$42M
- Provides 2025 Annual Guidance of $178 - $182 Million in Revenue and $38 - $42 Million of Adjusted EBITDA, Representing Year-Over-Year Increase of 13% in Revenues and 19% in Adjusted EBITDA Based on Mid-Point of 2024 Annual Guidance
- Expects to Achieve 2024 Guidance of $158 - $162 Million in Revenue and $32 - $35 Million of Adjusted EBITDA; 2024 Year-End Cash of $78 Million
- Aiming to Secure New Business Development and M&A Transactions During 2025 that Leverage Overall Financial Strength and Existing Commercial Infrastructure to Accelerate Long-Term Growth
- Expansion of Plasma Collection Operations with Opening of a Third Center by End of Q1 2025
- Based on Positive Feedback from U.S. FDA, Kamada Plans to Reduce Inhaled AAT Clinical Study Sample Size to Approximately 180 Patients; Interim Futility Analysis Planned by End of 2025
- 提供2025年度营业收入指导为178 - 18200万美元,调整后的EBITDA为38 - 4200万美元,较2024年度指导中点相比,营业收入同比增长13%,调整后的EBITDA同比增长19%。
- 预计实现2024年度营业收入指导为158 - 16200万美元,调整后的EBITDA为32 - 3500万美元;2024年末现金为7800万美元。
- 旨在2025年确保新的业务发展和并购交易,利用整体财务实力和现有商业制造行业来加速长期增长。
- 在2025年第一季度结束前扩大血浆采集运营,开设第三个中心。
- 基于美国FDA的积极反馈,Kamada计划将吸入AAt临床研究的样本量减少至大约180名患者;计划在2025年底进行中期无效性分析。